GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

NXP800   Click here for help

GtoPdb Ligand ID: 14086

Synonyms: CCT361814 | compound 22 [PMID: 37017629] | NXP-800
Compound class: Synthetic organic
Comment: NXP800 (CCT361814) was identified as an orally bioavailable heat shock factor 1 (HSF1) pathway inhibitor in a phenotypic screen [3]. It was proposed for anti-proliferative activity in tumours. Subsequent studies identified NXP800 as an activator of the GCN2 (general control nonderepressible 2) kinase that phosphorylates eukaryotic translation initiation factor 2 alpha (EIF2α) [2]. This activity promotes selective ATF4-mediated transcription of genes involved in the integrated stress response (ISR), ultimately leading to apoptosis of tumour cells [4].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 95.5
Molecular weight 569.63
XLogP 0.57
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CCN1CCN(CC1)CC2=CC=C3C=C(C=CC3=N2)C(=O)NC4=CC(=CC=C4F)NC(=O)C5=CC=C6C(=C5)OCCO6
Isomeric SMILES CCN1CCN(CC1)CC2=NC3=C(C=C2)C=C(C=C3)C(=O)NC4=C(C=CC(=C4)NC(=O)C5=CC6=C(C=C5)OCCO6)F
InChI InChI=1S/C32H32FN5O4/c1-2-37-11-13-38(14-12-37)20-25-6-3-21-17-22(4-9-27(21)34-25)32(40)36-28-19-24(7-8-26(28)33)35-31(39)23-5-10-29-30(18-23)42-16-15-41-29/h3-10,17-19H,2,11-16,20H2,1H3,(H,35,39)(H,36,40)
InChI Key UBALMDIKIGDHJW-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
NXP800 was advanced to clinical evaluation to determine safety and efficacy for the treatment of bile duct cancer (cholangiocarcinoma) [2]. Development for ovarian cancer was discontinued in mid-2025 due to lack of observed efficacy in the phase 1b study.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06420349 NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma Phase 1 Interventional Mayo Clinic 2
NCT05226507 A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer Phase 1 Interventional Nuvectis Pharma, Inc.